- Home
- QNRX vs CDT Comparison
QNRX vs CDT Comparison
Compare QNRX & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- CDT
- Stock Information
- Founded
- QNRX 2018
- CDT 2019
- Country
- QNRX United States
- CDT United States
- Employees
- QNRX N/A
- CDT N/A
- Industry
- QNRX Medical/Dental Instruments
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- CDT Health Care
- Exchange
- QNRX Nasdaq
- CDT Nasdaq
- Market Cap
- QNRX 4.4M
- CDT 4.6M
- IPO Year
- QNRX N/A
- CDT N/A
- Fundamental
- Price
- QNRX $7.36
- CDT $0.60
- Analyst Decision
- QNRX
- CDT
- Analyst Count
- QNRX 0
- CDT 0
- Target Price
- QNRX N/A
- CDT N/A
- AVG Volume (30 Days)
- QNRX 2.5K
- CDT 2.2M
- Earning Date
- QNRX 11-06-2025
- CDT 08-14-2025
- Dividend Yield
- QNRX N/A
- CDT N/A
- EPS Growth
- QNRX N/A
- CDT N/A
- EPS
- QNRX N/A
- CDT N/A
- Revenue
- QNRX N/A
- CDT N/A
- Revenue This Year
- QNRX N/A
- CDT N/A
- Revenue Next Year
- QNRX N/A
- CDT N/A
- P/E Ratio
- QNRX N/A
- CDT N/A
- Revenue Growth
- QNRX N/A
- CDT N/A
- 52 Week Low
- QNRX $5.01
- CDT $0.57
- 52 Week High
- QNRX $54.95
- CDT $274.80
- Technical
- Relative Strength Index (RSI)
- QNRX 46.17
- CDT 14.20
- Support Level
- QNRX $7.37
- CDT $0.57
- Resistance Level
- QNRX $7.79
- CDT $1.36
- Average True Range (ATR)
- QNRX 0.14
- CDT 0.09
- MACD
- QNRX 0.03
- CDT -0.06
- Stochastic Oscillator
- QNRX 39.44
- CDT 2.36
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.